SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TOSHI

TOSHI is trending as investors speculate on potential Coinbase and Binance listings, fueling community excitement around its status as the leading cat-themed coin on the Base network. Participants are actively debating the timing of a breakout while discussing long-term accumulation strategies and the token's utility within the evolving Base ecosystem.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing heightened trading volume and speculative interest as traders debate whether current price action signals a technical breakout or another cycle of retail volatility. The community remains deeply divided, with bulls pointing to the project's data-ownership narrative and potential ecosystem expansion, while bears highlight long-standing skepticism toward leadership and concerns over the token's historical performance relative to broader market momentum.

Dave & Buster's Entertainment, Inc. engages in the ownership and operation of entertainment and dining venues under the name Dave & Buster's. It offers a full menu of entrées and appetizers, a selection of alcoholic and non-alcoholic beverages, and an assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Coppell, TX.

Dave & Buster`s Entertainment Inc

Dave & Buster's Entertainment

Dave & Buster's is currently a focal point for traders due to intense volatility and speculation regarding its high short interest, which has fueled ongoing discussions about a potential short squeeze. Community sentiment is deeply divided, with many debating whether the companys recent operational hurdles and financial pressures present a genuine bankruptcy risk or a deep-value turnaround opportunity for long-term investors.

Spitcoin is a community-driven cryptocurrency built on the Solana blockchain that powers a decentralized creator economy through the LimitlessFlo platform.  The project focuses on giving creators full control over their content and earnings by enabling instant monetization from day one—through tips, subscriptions, live streaming, and marketplace transactions—without the restrictions of traditional platforms like bans, algorithm suppression, or delayed payouts.  At its core, Spitcoin is about combining meme culture with real utility, creating a self-sustaining ecosystem where platform activity drives token demand, and token usage fuels platform growth.

SpitCoin

Community members are actively highlighting SPITCOIN's role in powering the LimitlessFlo ecosystem while noting strong strategic alignment and whale accumulation alongside WAGMI. Traders are focused on the project's growth potential and are calling for increased visibility and data integration across tracking platforms.

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

Sui is gaining momentum as traders respond to positive network metrics and the prospect of upcoming institutional integration through anticipated derivative products. The community remains focused on accumulation and long-term potential, with active discussions debating whether current price levels offer a strategic entry point before a broader trend reversal.

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in Brisbane, CA.

Nurix Therapeutics Inc

Nurix Therapeutics is gaining attention as investors weigh the potential of its targeted protein degradation platform against the challenges of a capital-intensive biotech environment, with the community closely tracking upcoming data readouts and the potential for strategic M&A interest. Supporters emphasize the mechanistic advantages of the company's degrader pipeline, while skeptics remain focused on cash burn and the long-term need for additional funding.

ElizaOS

ElizaOS is facing intense debate as investors clash over allegations of internal manipulation and potential fraud, while others defend the project by betting on its long-term potential as an AI-agent operating system. This polarization is driving high trading activity and significant community discourse regarding the project's legitimacy.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is trending as investors debate the potential for long-term utility versus short-term price stagnation and ongoing token dilution. The community remains deeply divided, with many actively accumulating at current levels in anticipation of a breakthrough, while others express frustration over lackluster price action compared to other assets.

StupidCoin

The StupidCoin community is actively debating the project's legitimacy amidst claims of copycat tokens while sentiment remains bullish on recent chart patterns and potential viral growth. Supporters are framing the asset as a long-term hold, often drawing comparisons to other viral meme coins within the broader Solana ecosystem.

Frequency Electronics, Inc. engages in the design, development, and manufacture of precision time and frequency generation technology. It operates through the FEI-NY and FEI-Zyfer business segments. The FEI-NY segment provides precision time, frequency generation, and synchronization products and subsystems that are found on-board satellites, in ground-based communication stations, and imbedded in moving platforms. The FEI-Zyfer segment designs, develops, and manufactures products for precision time and frequency generation and synchronization, primarily incorporating GPS technology. The company was founded by Martin B. Bloch on August 25, 1961 and is headquartered in Uniondale, NY.

Frequency Electronics, Inc.

Frequency Electronics is trending as investors react to the company's upbeat guidance for long-term revenue growth and its strategic position within the expanding space and defense sectors. The community is actively discussing the stock's potential for a significant re-evaluation as they monitor ongoing backlog conversion and the promise of future contract wins.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corcept Therapeutics (NASDAQ:CORT) Upgraded by Zacks Research to Hold Rating

Zacks Research upgraded shares of Corcept Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Monday...

HC Wainwright Issues Optimistic Outlook for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Equities research analysts at HC Wainwright raised their Q3 2026 earnings per share estimates for Corcept Therapeutics in a research...

Corcept Therapeutics Incorporated $CORT Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH decreased its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 70.8% in the 4th quarter, according to its most...

Corcept Therapeutics (NASDAQ:CORT) Stock Price Up 7.9%  - Time to Buy?

Corcept Therapeutics (NASDAQ:CORT) Trading 7.9% Higher - Time to Buy...

CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised

Corcept Q1 loss meets estimates, while revenues miss. The company boosts 2026 outlook as new drug Lifyorli and rising Korlym demand reshape growth trajectory.

Corcept Therapeutics (NASDAQ:CORT) Announces Earnings Results

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.30) EPS for the quarter, missing the consensus estimate of...

Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates

Corcept (CORT) delivered earnings and revenue surprises of -1.11% and -4.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics Q1 Earnings Call Highlights

Corcept Therapeutics (NASDAQ:CORT) reported first-quarter 2026 revenue of $164.9 million, up from $157.2 million in the prior-year period, and raised its full-year 2026 revenue guidance to a range of $950 million to $1.05 billion. The company also reported a net loss of $31.8 million for the quarter...

Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and...

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

CORT
Corcept Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest CORT News

CORTCorcept Therapeutics Inc